Loading…
the sparker alert will let you know when a significant move starts with an audio alert, so You'll never miss an Opportunity.
Nuvation Bio Inc Is A Biopharmaceutical Company Tackling Unmet Needs In Oncology By Developing Differentiated And Novel Therapeutic Candidates. Its Product Candidate, Taletrectinib, Is An Oral, Potent, Central Nervous System-Active, Selective, Next-Generation C-Ros Oncogene 1 (Ros1) Inhibitor Designed For The Treatment Of Patients With Ros1+ Non-Small Cell Lung Cancer (Nsclc). In Addition, Its Clinical-Stage Pipeline Includes Oncology Product Candidates Such As Safusidenib, Nuv-1511, And Nuv-868 In Different Stages Of Development. The Company Generates Revenue From Out-Licensing Collaborative Agreements, Including Product Revenue, Upfront License Fees, Royalty Revenue, And Research And Development Services Revenue. The Company Generates The Majority Of Its Revenue From Japan.